Oncotarget

Research Papers:

Safety and effectiveness of FOLFOXIRI plus molecular target drug therapy for metastatic colorectal cancer: A multicenter retrospective study

Takatsugu Ogata, Hironaga Satake _, Misato Ogata, Yukimasa Hatachi, Hayato Maruoka, Daisuke Yamashita, Hiroki Hashida, Madoka Hamada and Hisateru Yasui

PDF  |  Full Text  |  How to cite  |  Order a Reprint

Oncotarget. 2019; 10:1070-1084. https://doi.org/10.18632/oncotarget.26626

Metrics: PDF 608 views  |   Full Text 652 views  |   ?  


Abstract

Takatsugu Ogata1, Hironaga Satake2, Misato Ogata1, Yukimasa Hatachi1, Hayato Maruoka3, Daisuke Yamashita4, Hiroki Hashida5, Madoka Hamada6 and Hisateru Yasui1

1Department of Medical Oncology, Kobe City Medical Center General Hospital, Kobe, Hyogo, Japan

2Cancer Treatment Center, Kansai Medical University Hospital, Hirakata, Osaka, Japan

3Department of Clinical Laboratory, Kobe City Medical Center General Hospital, Kobe, Hyogo, Japan

4Department of Pathology, Kobe City Medical Center General Hospital, Kobe, Hyogo, Japan

5Department of Surgery, Kobe City Medical Center General Hospital, Kobe, Hyogo, Japan

6Department of Surgery, Kansai Medical University Hospital, Hirakata, Osaka, Japan

Correspondence to:

Hironaga Satake, email: takeh1977@gmail.com

Keywords: metastatic colorectal cancer; FOLFOXIRI therapy; triplet; anti-EGFR antibodies; anti-VEGF antibodies

Received: November 02, 2018     Accepted: January 11, 2019     Published: February 01, 2019

ABSTRACT

Introduction: FOLFOXIRI plus bevacizumab has a promising efficacy as first-line systemic chemotherapy for metastatic colorectal cancer (mCRC). This study aimed to evaluate the safety and effectiveness of FOLFOXIRI plus antibodies.

Results: Fifty-five patients were enrolled (median age: 60 years, males: 25, females: 30). Twenty-six subjects had RAS mutations and 29 had RAS wild-type. Anti-VEGF and anti-EGFR antibodies were administered to 38 and 17 patients, respectively. The most common severe adverse event was neutropenia (51%). The overall response rate (ORR) was 69% (55% with anti-VEGF antibodies and 100% with anti-EGFR antibodies; P = 0.190), and the disease control rate was 98% (stable disease: 16 patients). With a median follow-up period of 18.4 months, the median progression-free survival (mPFS) was 11.0 months and the median overall survival (mOS) was 41.9 months. The mPFS and mOS did not significantly differ between patients treated with anti-EGFR antibodies and those with anti-VEGF antibodies.

Methods: We retrospectively collected data from mCRC patients treated with FOLFOXIRI plus antibodies between March 2014 and December 2017.

Conclusions: FOLFOXIRI plus antibody therapy was effective in patients with mCRC. The response rate was higher in patients treated with anti-EGFR antibodies than in those treated with anti-VEGF antibodies.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 26626